Program

WEDNESDAY MAY 23, 2001

10:30-12:00	Concurrent Podium Sessions CARDIOVASCULAR DISEASE, SESSION 2 CV5 THE COST-EFFECTIVENESS OF LIFETIME FACTOR VIII PROPHYLAXIS IN THE TREATMENT OF SEVERE HEMOPHILIA A Charles RA1, Hay J2, 1University of Southern California, School of Pharmacy, Los Angeles, CA, USA; 2University of Southern California, Los Angeles, CA, USA CV6 ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS Risebrough NA, Mittmann N, HOPE Research Centre, Toronto, ON, Canada CV7 COST-EFFECTIVENESS OF CARDIOVASCULAR DISEASE (CVD) PREVENTION BY REDUCING POSTPRANDIAL HYPERGLYCEMIA Glick H1, Qiao Q2, Grueger J3, 1University of Pennsylvania, Philadelphia, PA, USA; 2National Public Health Institute, Helsinki, Finland; 3Novartis Pharmaceuticals AG, Basel, Switzerland CV8 WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION Erickson SR1, McBurney CR12, Kline-Rogers EM1, Cooper JV1, Mani OCM1, Eagle KA1, 1University of Michigan, Ann Arbor, MI, USA; 2Pfizer Inc., Ann Arbor, MI, USA MENTAL HEALTH MH1 THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC medications ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA Mulani P, McCombs J, University of Southern California, Los Angeles, CA, USA MH2 FUTURE EMPLOYABILITY: A NEW APPROACH TO COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTIC THERAPY Ganguly R, Miller LS, Martin BC, University of Georgia, Athens, GA, USA MH3 CLiNICAL ASSESSMENT OF QUALITY OF LIFE AMONG SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME Russo P1, Kirkpatrick B2, 1The MEDSTAT Group Inc, Washington, DC, USA; 2University of Maryland Psychiatric Research Center, Baltimore, MD, USA MH4 APPLICATION OF THE RASCH MODEL TO THE SF36 MENTAL HEALTH 5 ITEM SCALE (MH5) Perneger TV, Bovier PA, Geneva University Hospital, Geneva, Switzerland MUSCULAR-SKELETAL DISORDERS MS1 COST-EFFECTIVENESS OF INTERVENTIONS FOR LATERAL EPICONDYLITIS: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE Korthals-de Bos IBC, Smidt N, Tulder M, Bouter L, Vrije Universiteit Amsterdam, Amsterdam, Netherlands MS2 RESPONSIVENESS TO CHANGE OF THE SF-36 IN RAPOLO, A LONGITUDINAL STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT Lubeck DP1, Yelin E1, Katz P1, Roepke L1, Wanke LA2, Buatti M3, 1University of California-San Francisco, San Francisco, CA, USA; 2Immunex Corporation, Seattle, WA, USA; 3Wyeth-Ayerst Research, Philadelphia, PA, USA MS3 CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT Kim SS, Drabinski AM, Williams GR, Formica CA, Knoll Pharmaceutical Company, Mount Olive, NJ, USA MS4 A SYSTEMATIC REVIEW OF HEALTH STATE VALUES FOR OSTEOPOROSIS RELATED CONDITIONS Brazier JE1, Green C2, Kanis J1, 1University of Sheffield, Sheffield, UK; 2MEDTAP UK, London, UK RESPIRATORY DISORDERS/DISEASES RS1 OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA: A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE Chiou CF1, Weaver MR2, Bell MA2, 1Zynx Health Inc.-a subsidiary of Cedars-Sinai Health System, Beverly Hills, CA, USA; 2University of Washington, Seattle, WA, USA RS2 USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE Szende A1, Meszaros A2, Berta GY3, Stahl E4, Svensson K4, 1AstraZeneca, Torokbalint, Hungary; 2Semmelweis Medical University, Budapest, Hungary; 3Hospital for Chest Diseases, Mosdos, Hungary; 4AstraZeneca R&D Lund, Lund, Sweden RS3 PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE: A NEW, PATIENT-BASED MEASURE OF SYMPTOMS IN COMMUNITY ACQUIRED PNEUMONIA Lamping D1, Schroter S1, Sagnier PP2, Duprat-Lomon I2, 1London School of Hygiene & Tropical Medicine, London, UK; 2Bayer Plc, Slough, UK RS4 A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA Paltiel A1, Fuhlbrigge A2, Kitch B2, Weiss S2, Neumann P3, Kuntz K3, 1Yale School of Medicine, New Haven, CT, USA; 2Harvard School of Medicine, Boston, MA, USA; 3Harvard School of Public Health, Boston, MA, USA
9:30-10:00	Break
10:00-12:00	Third Plenary Session — "The Bleeding Edge of Decision-making in Managing Healthcare Systems: Is Cost-effectiveness Appropriate for Decision-makers" Objectives: To reveal how selected organizations are using pharmacoeconomic methods in decision-making; to provide examples of the way that cost analysis are operationalized; to consider if 'right' decisions are being made? Moderator & Speaker: Michael Drummond PhD, University of York, Centre for Health Economics, York, UK Speakers: Andreas Laupacis MD, MSc, FRCPC, President and CEO, Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada; David Campen, MD, Medical Director, Drug Information Professional Services, Kaiser-Permanente Northern California, Oakland, California, USA; D.S. Pete Fullerton PhD, Vice President, Regence BlueShield, Seattle, Washington, USA
12:00	Adjournment